Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections

被引:78
作者
Kwa, Andrea L. H. [2 ]
Lim, Tze-Peng [2 ]
Low, Jenny G. H. [3 ]
Hou, JingGuo [1 ]
Kurup, Asok [3 ]
Prince, Randall A. [1 ]
Tam, Vincent H. [1 ]
机构
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] Singapore Gen Hosp, Dept Pharm, Singapore 169608, Singapore
[3] Singapore Gen Hosp, Dept Internal Med, Div Infect Dis, Singapore 169608, Singapore
关键词
pharmacokinetics; polymyxin B; multidrug-resistant infections;
D O I
10.1016/j.diagmicrobio.2007.08.008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Polymyxin B is increasingly used clinically for the treatment of multidrug-resistant Gram-negative infections, despite very limited understanding of its disposition in humans. The disposition of intravenous polymyxin B1 in 9 adult patients was characterized. Random blood samples (specifically timed in relation to the dose administered) were obtained, and the serum concentrations of polymyxin B1 were assayed using a validated methodology by liquid chromatography mass spectroscopy. The serum concentration profiles of all the patients were analyzed by a population pharmacokinetic analysis using the nonparametric adaptive grid program, The mean volume of distribution and elimination half-life were found to be 47.2 L and 13.6 h, respectively. This is the 1st case series to date in which the pharmacokinetics of polymyxin B1 after intravenous administration are described. The results of the series in conjunction with pharmacodynamic and susceptibility surveillance studies could facilitate an approach to the design of optimal dosing regimens. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:163 / 167
页数:5
相关论文
共 13 条
[2]   Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria [J].
Evans, ME ;
Feola, DJ ;
Rapp, RP .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (09) :960-967
[3]   Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections [J].
Falagas, ME ;
Kasiakou, SK .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :1333-1341
[4]   Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B [J].
Landman, D ;
Bratu, S ;
Alam, M ;
Quale, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) :954-957
[5]   An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) population models [J].
Leary, R ;
Jelliffe, R ;
Schumitzky, A ;
Van Guilder, M .
FOURTEENTH IEEE SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS, PROCEEDINGS, 2001, :389-394
[6]   Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii [J].
Levin, AS ;
Barone, AA ;
Penço, J ;
Santos, MV ;
Marinho, IS ;
Arruda, EAG ;
Manrique, EI ;
Costa, SF .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1008-1011
[7]   Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis [J].
Li, J ;
Coulthard, K ;
Milne, R ;
Nation, RL ;
Conway, S ;
Peckham, D ;
Etherington, C ;
Turnidge, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) :987-992
[8]   Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography [J].
Li, J ;
Milne, RW ;
Nation, RL ;
Turnidge, JD ;
Coulthard, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1364-1370
[9]   Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography [J].
Li, J ;
Milne, RW ;
Nation, RL ;
Turnidge, JD ;
Coulthard, K ;
Valentine, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) :3304-3307
[10]   Liquid chromatography of polymyxin B sulphate [J].
Orwa, JA ;
Van Gerven, A ;
Roets, E ;
Hoogmartens, J .
JOURNAL OF CHROMATOGRAPHY A, 2000, 870 (1-2) :237-243